AAV-LRRK2 IND-Enabling Study Design

Experiment Category: Gene Therapy / IND-Enabling Preclinical Studies Created: 2026-03-21 Based on: AAV Serotype Comparison for [LRRK2](/entities/lrrk2) (/experiments/aaav-serotype-comparison-lrrk2)

Executive Summary

This document outlines comprehensive IND-enabling preclinical studies for AAV-LRRK2 gene therapy targeting Parkinson's disease. Building on our serotype comparison results demonstrating AAV-PHP.B as the optimal vector, we propose a complete package including GLP toxicology, biodistribution, dose escalation, and long-term NHP safety studies to support an IND submission to the FDA.

Background and Rationale

LRRK2 (Leucine-Rich Repeat Kinase 2) mutations are the most common cause of autosomal-dominant Parkinson's disease, accounting for 5-10% of familial PD cases. Our prior serotype comparison study identified AAV-PHP.B as demonstrating superior transduction efficiency and reduced immunogenicity compared to traditional serotypes (AAV2, AAV5, AAV9) in both mouse and NHP brain tissue.

The IND-enabling studies outlined below are designed to generate the safety, toxicity, and efficacy data required by FDA 21 CFR 312.23 for a gene therapy IND application.

Study 1: GLP Single-Dose Toxicology Study

Study Objectives

• Evaluate the safety and tolerability of a single intracerebral dose of AAV-PHP.B-shLRRK2 in rats and non-human primates
• Identify target organs, dose-limiting toxicities, and maximum tolerated dose (MTD)
• Generate GLP-compliant data for IND submission

Study Design

...

Experiment Category: Gene Therapy / IND-Enabling Preclinical Studies Created: 2026-03-21 Based on: AAV Serotype Comparison for [LRRK2](/entities/lrrk2) (/experiments/aaav-serotype-comparison-lrrk2)

Executive Summary

This document outlines comprehensive IND-enabling preclinical studies for AAV-LRRK2 gene therapy targeting Parkinson's disease. Building on our serotype comparison results demonstrating AAV-PHP.B as the optimal vector, we propose a complete package including GLP toxicology, biodistribution, dose escalation, and long-term NHP safety studies to support an IND submission to the FDA.

Background and Rationale

LRRK2 (Leucine-Rich Repeat Kinase 2) mutations are the most common cause of autosomal-dominant Parkinson's disease, accounting for 5-10% of familial PD cases. Our prior serotype comparison study identified AAV-PHP.B as demonstrating superior transduction efficiency and reduced immunogenicity compared to traditional serotypes (AAV2, AAV5, AAV9) in both mouse and NHP brain tissue.

The IND-enabling studies outlined below are designed to generate the safety, toxicity, and efficacy data required by FDA 21 CFR 312.23 for a gene therapy IND application.

Study 1: GLP Single-Dose Toxicology Study

Study Objectives

• Evaluate the safety and tolerability of a single intracerebral dose of AAV-PHP.B-shLRRK2 in rats and non-human primates
• Identify target organs, dose-limiting toxicities, and maximum tolerated dose (MTD)
• Generate GLP-compliant data for IND submission

Study Design

| Parameter | Rats | Non-Human Primates |
|-----------|------|-------------------|
| Species | Sprague-Dawley | Cynomolgus macaques |
| Age | 8-10 weeks | 3-5 years |
| Groups | 4 (3 dose + 1 control) | 4 (3 dose + 1 control) |
| Males/Females | 10/sex/group | 3/sex/group |
| Doses | Low: 1×10^13 GC, Mid: 3×10^13 GC, High: 1×10^14 GC | Low: 1×10^13 GC, Mid: 3×10^13 GC, High: 1×10^14 GC |
| Route | Intracerebral (stereotactic) | Intracerebral (stereotactic) |
| Observation | 28 days | 90 days |

Primary Endpoints

• Clinical observations (neurological, behavioral, physical)
• Body weight and food consumption
• Clinical pathology (hematology, clinical chemistry, coagulation)
• Gross necropsy and organ weights
• Histopathology (including brain, liver, kidney, spleen, heart, lung)
• Immunogenicity (anti-AAV antibodies, T-cell responses)

Secondary Endpoints

• Biodistribution (qPCR for vector genome copy number)
• LRRK2 mRNA expression in target tissues
• Biomarker analysis ([NfL](/biomarkers/neurofilament-light-chain-nfl), [tau](/proteins/tau), [α-synuclein](/proteins/alpha-synuclein) in CSF)
• Cytokine/chemokine panels

Budget Estimate

| Item | Cost |
|------|------|
| GLP study contract (CRO) | $450,000 |
| Vector production (GLP grade) | $120,000 |
| Histopathology | $85,000 |
| Bioanalysis | $65,000 |
| Report writing | $35,000 |
| Total | $755,000 |

Study 2: Biodistribution Study

Study Objectives

• Determine vector genome distribution following intracerebral administration
• Identify off-target tissues and persistence
• Characterize shedding characteristics

Study Design

| Parameter | Mice | NHPs |
|-----------|------|------|
| Species | C57BL/6 | Cynomolgus macaques |
| Groups | 5 timepoints | 3 timepoints |
| Timepoints | 1, 7, 28, 90, 180 days | 7, 90, 180 days |
| Tissues collected | 25 tissues | 30 tissues |
| Samples per timepoint | 10 animals | 3 animals |

Tissues to Analyze

• Brain (injected region, contralateral, [cortex](/brain-regions/cortex), cerebellum)
• Spinal cord
• Liver
• Spleen
• Kidney
• Heart
• Lung
• Testis/Ovary
• Drainage lymph nodes
• Blood (plasma, PBMCs)

Analytical Methods

• Droplet digital PCR (ddPCR) for vector genome quantification
• RNAseq for transcriptional changes
• ELISA for protein expression

Budget Estimate

| Item | Cost |
|------|------|
| Vector production | $50,000 |
| Tissue processing | $35,000 |
| ddPCR analysis | $45,000 |
| RNAseq | $30,000 |
| Report | $15,000 |
| Total | $175,000 |

Study 3: Dose-Range Finding Study

Study Objectives

• Establish dose-response relationship for efficacy
• Identify no-observed-adverse-effect level (NOAEL)
• Support dose selection for pivotal studies

Study Design

| Parameter | Rats |
|-----------|------|
| Groups | 5 (4 dose + 1 vehicle) |
| Dose range | 1×10^11 to 1×10^14 GC |
| Route | Intracerebral |
| Duration | 90 days |
| Animals | 15/sex/group |

Efficacy Readouts

• LRRK2 mRNA knockdown (qPCR)
• LRRK2 protein expression (Western blot, IHC)
• Tyrosine hydroxylase (TH) neuron survival
• Behavioral testing (cylinder, rotarod, gait analysis)
• Neuroinflammation markers (Iba1, GFAP)

Budget Estimate

| Item | Cost |
|------|------|
| Vector production | $80,000 |
| In-life phase | $95,000 |
| Tissue analysis | $55,000 |
| Behavioral testing | $25,000 |
| Report | $20,000 |
| Total | $275,000 |

Study 4: Long-Term NHP Safety Study

Study Objectives

• Evaluate safety of long-term LRRK2 knockdown
• Assess durability of therapeutic effect
• Characterize late-onset toxicity (12 months)

Study Design

| Parameter | Specification |
|-----------|---------------|
| Species | Cynomolgus macaques |
| Groups | 4 (3 dose + 1 control) |
| Doses | Low: 1×10^13 GC, Mid: 3×10^13 GC, High: 1×10^13 GC |
| Animals | 6/sex/group (48 total) |
| Duration | 12 months |
| Route | Bilateral intraparenchymal (SNc + striatum) |

Enhanced Monitoring

• Monthly neurological examinations
• Quarterly CSF collection (cell count, protein, NfL, tau, α-syn)
• PET imaging (DAT, TH) at baseline, 6, 12 months
• Comprehensive behavioral assessment

Histopathology Battery

• Full neural axis examination
• Peripheral organ toxicity
• Reproductive organ assessment
• Electron microscopy of target [neurons](/entities/neurons)

Budget Estimate

| Item | Cost |
|------|------|
| NHP procurement & holding | $720,000 |
| Vector production | $180,000 |
| In-life monitoring | $250,000 |
| Imaging (PET) | $120,000 |
| CSF analysis | $85,000 |
| Histopathology | $150,000 |
| Bioanalysis | $75,000 |
| Report writing | $60,000 |
| Total | $1,640,000 |

Manufacturing Scale-Up Plan

Current State (Research Grade)

• Production scale: 1-5 × 10^14 GC per batch
• System: Triple transfection in HEK293 cells
• Purification: CsCl gradient or affinity chromatography

Target State (GMP Grade)

• Production scale: 1-5 × 10^16 GC per batch
• Scale-up pathway:

| Phase | Scale | Timeline | Purpose |
|-------|-------|----------|---------|
| Pilot | 10^15 GC | Months 1-3 | Process development |
| Demo | 5×10^15 GC | Months 4-6 | Validation batches |
| GMP Batch 1 | 1×10^16 GC | Months 7-9 | GLP toxicology |
| GMP Batch 2 | 1×10^16 GC | Months 10-12 | Pivotal studies |
| GMP Batch 3 | 1×10^16 GC | Months 13-15 | IND filing |

Manufacturing Partners (Pre-qualified)

| Company | Location | Capability |
|---------|----------|------------|
| Vigene Biosciences | USA (MD) | AAV GMP, 200L+ |
| Catalent | USA (NJ) | AAV GMP, 1000L |
| Oxford BioMedica | UK | Lentivirus/AAV GMP |
| Thermo Fisher | USA | GMP manufacturing |
| Charles River Labs | USA | GLP/GMP toxicology |

CMC Requirements for IND

| Requirement | Specification |
|-------------|---------------|
| Identity | Sequencing, restriction analysis |
| Purity | >95% empty capsids, <3% host cell DNA |
| Potency | Transduction units (TU) per mL |
| Stability | 24 months at -80°C |
| Sterility | No growth in sterility tests |
| Endotoxin | <0.5 EU/mL |

Manufacturing Cost Estimate

| Item | Cost |
|------|------|
| Process development | $200,000 |
| GMP vector production (3 batches) | $600,000 |
| Analytical testing | $150,000 |
| Fill/finish | $75,000 |
| Stability studies | $100,000 |
| Quality release | $50,000 |
| Total | $1,175,000 |

Regulatory Strategy

Regulatory Pathway

• Product Type: Gene therapy (AAV vector)
• Route: Intracerebral (intraparenchymal)
• Classification: Biological, Section 351(a) (Live recombinant virus)
• FDA Division: Center for Biologics Evaluation and Research (CBER)

Pre-IND Package

| Document | Status | Timeline |
|----------|--------|----------|
| Product description | To be prepared | Month 1-2 |
| Manufacturing summary | To be prepared | Month 1-3 |
| Preclinical data package | To be prepared | Month 3-6 |
| IND application | To be filed | Month 9 |

Pre-IND Meeting Request

• Timing: Prior to IND submission
• Topics: Study design, CMC requirements, regulatory expectations
• FDA Office: Office of Cellular, Tissue, and Gene Therapies (OCTGT)

Key Regulatory Considerations

Efficacy Endpoints: Discuss with FDA on appropriate biomarkers vs. clinical endpoints

Animal Model Requirements: Demonstrate relevance to human disease

Dose Selection: Provide scientific rationale based on NHP data

Manufacturing Changes: Minimize between toxicology and clinical batches

Risk Mitigation: Immune response management strategy

Regulatory Timeline

| Milestone | Target Date |
|-----------|-------------|
| Pre-IND meeting | Month 6 |
| IND submission | Month 9 |
| IND clearance | Month 12 |
| First patient dosing | Month 15 |

Estimated Regulatory Costs

| Item | Cost |
|------|------|
| Regulatory consulting | $75,000 |
| Pre-IND meeting preparation | $25,000 |
| IND application assembly | $35,000 |
| FDA user fees | $2,478 (IND) |
| Post-IND support | $50,000 |
| Total | $187,478 |

Integrated Timeline

gantt
title AAV-LRRK2 IND-Enabling Studies Timeline
dateFormat YYYY-MM
section Manufacturing
Process Development :2026-04, 3
GMP Production Batch 1 :2026-07, 3
GMP Production Batch 2 :2026-10, 3
GMP Production Batch 3 :2027-01, 3
section GLP Toxicology
Single-Dose Toxicology :2026-07, 6
Long-Term NHP Study :2026-10, 12
section Other Studies
Biodistribution :2026-07, 6
Dose-Range Finding :2026-07, 4
section Regulatory
Pre-IND Meeting :2026-09, 1
IND Submission :2026-12, 1

Total Budget Summary

| Category | Cost |
|----------|------|
| GLP Toxicology | $755,000 |
| Biodistribution | $175,000 |
| Dose-Range Finding | $275,000 |
| Long-Term NHP Safety | $1,640,000 |
| Manufacturing | $1,175,000 |
| Regulatory | $187,000 |
| TOTAL | $4,207,000 |

Risk Assessment and Mitigation

| Risk | Probability | Impact | Mitigation |
|------|-------------|--------|------------|
| NHP study delays | Medium | High | Contingency timeline, alternative CRO |
| Manufacturing failure | Low | High | Dual sourcing, process robustness |
| Regulatory hold | Low | High | Pre-IND communication, robust data |
| Immune response | Medium | Medium | Immunomodulation protocol |
| Efficacy signal weak | Medium | High | Dose optimization, alternative constructs |

Cross-Links to NeuroWiki Pages

• [LRRK2](/genes/lrrk2) - Target gene
• [LRRK2 Protein](/proteins/lrrk2-protein) - Protein product
• [Parkinson's Disease](/diseases/parkinsons-disease) - Target disease
• [AAV Vectors for Neurodegenerative Gene Therapy](/therapeutics/aav-vectors-neurodegenerative-gene-therapy) - Vector platform
• [Gene Therapy for Parkinson's](/therapeutics/gene-therapy-parkinsons) - Related treatment
• [G2019S LRRK2 Mutation](/diseases/lrrk2-g2019s-parkinsonism) - Common mutation
• [AAV Serotype Comparison Experiment](/experiments/aaav-serotype-comparison-lrrk2) - Prior work

Conclusion

This comprehensive IND-enabling study package provides a clear path from our promising preclinical data to an FDA IND submission for AAV-LRRK2 gene therapy in Parkinson's disease. The total investment of approximately $4.2M over 15-18 months positions the program for clinical development with a well-characterized, safe, and effective gene therapy candidate.

See Also

• [Mechanisms](/mechanisms)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [ClinicalTrials.gov](https://clinicaltrials.gov/)

References

Unknown, FDA Guidance: Gene Therapy Clinical Trials - Monitoring Participants (n.d.)

Unknown, FDA Guidance: Human Gene Therapy Products Incorporating Genome Editing (n.d.)

Unknown, ICH M3(R2) Guidance: Nonclinical Safety Studies for the Conduct of Human Clinical Trials (n.d.)

[Unknown, AAV Gene Therapy: Regulatory Considerations (Nature Reviews Drug Discovery) (n.d.)](https://doi.org/10.1038/s41573-021-00152-1)